SOPHiA GENETICS (SOPH) Competitors $2.96 -0.04 (-1.33%) As of 02:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SOPH vs. PHAR, IMNM, AVBP, CMRX, CDMO, GYRE, COGT, REPL, CRON, and VIRShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Pharming Group (PHAR), Immunome (IMNM), ArriVent BioPharma (AVBP), Chimerix (CMRX), Avid Bioservices (CDMO), Gyre Therapeutics (GYRE), Cogent Biosciences (COGT), Replimune Group (REPL), Cronos Group (CRON), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. Its Competitors Pharming Group Immunome ArriVent BioPharma Chimerix Avid Bioservices Gyre Therapeutics Cogent Biosciences Replimune Group Cronos Group Vir Biotechnology SOPHiA GENETICS (NASDAQ:SOPH) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Does the MarketBeat Community prefer SOPH or PHAR? Pharming Group received 4 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 67.65% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% Pharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Is SOPH or PHAR more profitable? Pharming Group has a net margin of -6.09% compared to SOPHiA GENETICS's net margin of -110.71%. Pharming Group's return on equity of -7.65% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% Pharming Group -6.09%-7.65%-3.82% Which has higher valuation and earnings, SOPH or PHAR? Pharming Group has higher revenue and earnings than SOPHiA GENETICS. Pharming Group is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$67.17M2.94-$78.98M-$1.00-2.96Pharming Group$320.71M2.54-$10.55M-$0.20-59.83 Does the media refer more to SOPH or PHAR? In the previous week, Pharming Group had 8 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 9 mentions for Pharming Group and 1 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.93 beat Pharming Group's score of 0.67 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Overall Sentiment SOPHiA GENETICS Positive Pharming Group Positive Do insiders and institutionals have more ownership in SOPH or PHAR? 31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, SOPH or PHAR? SOPHiA GENETICS has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Pharming Group has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Do analysts recommend SOPH or PHAR? SOPHiA GENETICS presently has a consensus target price of $6.80, indicating a potential upside of 129.73%. Pharming Group has a consensus target price of $30.00, indicating a potential upside of 150.73%. Given Pharming Group's stronger consensus rating and higher probable upside, analysts plainly believe Pharming Group is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPharming Group beats SOPHiA GENETICS on 10 of the 17 factors compared between the two stocks. Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.39M$3.11B$5.60B$8.63BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-2.7233.0627.2520.01Price / Sales2.94469.00412.71157.94Price / CashN/A168.6838.2534.64Price / BookN/A3.437.124.70Net Income-$78.98M-$72.35M$3.24B$248.05M7 Day Performance-2.95%7.86%2.75%2.62%1 Month Performance-6.92%18.41%9.00%6.32%1 Year Performance-38.33%-16.84%31.41%13.78% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS1.8284 of 5 stars$2.96-1.3%$6.80+129.7%-38.1%$197.39M$67.17M-2.72520News CoverageGap DownHigh Trading VolumePHARPharming Group2.0584 of 5 stars$11.81-0.4%$30.00+154.0%+32.9%$806.69M$320.71M-45.42280News CoverageShort Interest ↑IMNMImmunome1.7865 of 5 stars$9.27+1.5%$23.33+151.7%-39.6%$806.60M$10.94M-1.1440AVBPArriVent BioPharma1.4458 of 5 stars$23.60+0.3%$39.29+66.5%+24.4%$804.69MN/A-6.2640Positive NewsCMRXChimerix0.6755 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.8423 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading VolumeGYREGyre Therapeutics0.3365 of 5 stars$8.50+1.1%N/A-21.8%$796.94M$100.64M425.0040Short Interest ↓COGTCogent Biosciences2.4989 of 5 stars$6.90+1.5%$14.57+111.2%-17.7%$785.61MN/A-2.7880Positive NewsREPLReplimune Group4.504 of 5 stars$10.18-1.9%$20.83+104.6%+8.7%$784.75MN/A-3.32210Positive NewsCRONCronos Group1.9208 of 5 stars$1.96-1.0%N/A-21.0%$755.94M$124.59M-15.08450Positive NewsVIRVir Biotechnology3.0564 of 5 stars$5.43-0.4%$32.86+505.1%-50.6%$750.63M$14.30M-1.39580Positive News Related Companies and Tools Related Companies PHAR Alternatives IMNM Alternatives AVBP Alternatives CMRX Alternatives CDMO Alternatives GYRE Alternatives COGT Alternatives REPL Alternatives CRON Alternatives VIR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SOPH) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
